Home / Stocks / TFX

Teleflex (TFX, Health Care Equipment) Stock Valuation & Fair Value Fairly valued

Teleflex (TFX, Health Care Equipment) trades at a blended P/E of 17.7, about 11% below its historical normal valuation, with a forward growth estimate of 27.4% and a PEG of 0.65. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 19.9 on the same blended earnings, the 2026-09-18 close of $124.52 corresponds to about $140 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
17.7
Normal P/E
19.9
PEG
0.65
Fwd growth
27.4%
Div yield
1.1%
RSI (14)
26.2
Oversold
Technical context
  • Price $121.75 at the 2026-09-23 close, 9.1% below the 20-day average ($133.89) and 9.4% below the 50-day ($134.37).
  • RSI (14) at 26.2.
  • 52-week range $99.54 to $142.05: the price is 14.3% below the high and 22.3% above the low.

The Street vs SeerForecast

Wall Street's mean price target for TFX is $153.55 across 11 analysts, 26.1% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 19.8 to 17.7 between 2026-07-31 and 2026-09-21, against a normal P/E of 19.9, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 19.8, Fairly valued (recalculated)2026-08-03: P/E 20.4, Fairly valued2026-08-07: P/E 20.4, Fairly valued (recalculated)2026-08-10: P/E 19.2, Fairly valued2026-08-14: P/E 19.2, Fairly valued (recalculated)2026-08-17: P/E 19.5, Fairly valued2026-08-21: P/E 19.5, Fairly valued (recalculated)2026-08-24: P/E 19.8, Fairly valued2026-08-27: P/E 19.8, Fairly valued (recalculated)2026-08-28: P/E 19.8, Fairly valued (recalculated)2026-08-30: P/E 19.8, Fairly valued (recalculated)2026-08-31: P/E 19.9, Fairly valued2026-09-05: P/E 19.9, Fairly valued (recalculated)2026-09-07: P/E 19.7, Fairly valued2026-09-12: P/E 19.7, Fairly valued (recalculated)2026-09-14: P/E 18.6, Fairly valued2026-09-19: P/E 18.6, Fairly valued (recalculated)2026-09-21: P/E 17.7, Fairly valued18.019.020.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 19.9
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 19.8-0%Fairly valued
2026-08-03P/E 20.4+3%Fairly valued
2026-09-21P/E 17.7-11%Fairly valued ← now

Frequently asked questions

Is Teleflex stock overvalued?

At a blended P/E of 17.7 versus its historical normal P/E of 19.9, Teleflex trades about 11% below its typical valuation, with a PEG of 0.65 on 27.4% forward growth. tickerseer currently rates it fairly valued.

What is Teleflex's fair value and PEG?

Teleflex trades at a blended P/E of 17.7 against a historical normal P/E of 19.9, a PEG of 0.65, and a forward growth estimate of 27.4%. Priced at its historical normal P/E of 19.9 on the same blended earnings, the 2026-09-18 close of $124.52 corresponds to about $140 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Teleflex changed?

tickerseer's rating has been fairly valued since 2026-07-31.

What is the analyst price target for Teleflex?

The mean Wall Street price target for Teleflex is $153.55 across 11 analysts, 26.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track TFX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.